October 2021 OSE Immunotherapeutics Announces Evolution in Company’s Board of Directors and Management
October 2021 Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership
October 2021 OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi®
October 2021 OSE Immunotherapeutics Presenting at the Annual International Conference BIO-EUROPE SPRING
October 2021 OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi®